kabutan

Japan Tissue Engineering Co., Ltd.(7774) Summary

7774
TSE Growth
Japan Tissue Engineering Co., Ltd.
567
JPY
+2
(+0.35%)
Jan 29, 3:10 pm JST
3.70
USD
Jan 29, 1:10 am EST
Result
PTS
outside of trading hours
567.1
Jan 29, 3:07 pm JST
Summary Chart Historical News Financial Result
PER
158.8
PBR
4.22
Yield
ー%
Margin Trading Ratio
51.80
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
567 JPY 3.70 USD
Previous Close Jan 28
565 JPY 3.70 USD
High Jan 29, 9:35 am
578 JPY 3.78 USD
Low Jan 29, 1:43 pm
560 JPY 3.65 USD
Volume
98,300
Trading Value
0.06B JPY 0.36M USD
VWAP
568.55 JPY 3.71 USD
Minimum Trading Value
56,700 JPY 370 USD
Market Cap
0.02T JPY 0.15B USD
Number of Trades
252
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
362
1-Year High Apr 22, 2025
11,342
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 235,500 598,800 2.54
Jan 16, 2026 193,900 534,900 2.76
Jan 9, 2026 179,300 552,800 3.08
Dec 26, 2025 72,600 576,700 7.94
Dec 19, 2025 81,000 559,400 6.91
Company Profile
Japan Tissue Engineering Co., Ltd. is a regenerative medicine venture. The company develops autologous cultured epidermis and cartilage, among other products. It became a subsidiary of Teijin through a tender offer.
Sector
Precision Instruments
Japan Tissue Engineering Co., Ltd. focuses on the development, manufacturing, and sales of regenerative medicine products, as well as contracted regenerative medicine services for development and manufacturing, and research and development support. The company has five products: JACE (autologous cultured epidermis), JACC (autologous cultured cartilage), NEPIC (autologous cultured corneal epithelium), OCULAR (autologous cultured oral mucosal epithelium), and JASMINE (autologous cultured epidermis containing melanocytes). In its contracted regenerative medicine business, the company provides CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) services. The research and development support business offers the LabCyte series of human cultured tissues. As new pipelines, the company is working on the development of allogeneic cultured epidermis and CAR-T cell therapies. Japan Tissue Engineering Co., Ltd. is a member of the Teijin Group.